{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:39:37Z","timestamp":1773409177889,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>B cell-depleting therapies such as ocrelizumab (OCR) are highly effective in people with multiple sclerosis (MS). Especially at treatment start and initial infusion, infusion-related reactions (IRR) are a common adverse event. The relevance of acute changes of cell-depleting therapies on peripheral immune compartments and routine lab testing is important for clinical practice. We systematically analyzed routine blood parameters, detailed blood immunophenotyping and serum cytokine profiles in 45 MS patients starting on OCR. Blood samples were collected before and after corticosteroid premedication and directly after each OCR infusion of the first three ocrelizumab infusions. Blood B cells were rapidly depleted and accompanied only by a mild cytokine release at the first OCR infusion. Cytokine release was not significantly detectable from a third application in line with decreasing IRRs. B cell depletion was accompanied by short-lived changes in other immune cell populations in number, activation and cytokine secretion after each OCR infusion. Standard lab parameters did not show any clinically relevant changes. Our data demonstrate only mild changes during the first OCR infusion, which are not present any more during long-term treatment.<\/jats:p>","DOI":"10.3390\/ijms232213759","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T02:44:32Z","timestamp":1667961872000},"page":"13759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1371-5032","authenticated-orcid":false,"given":"Katja","family":"Akg\u00fcn","sequence":"first","affiliation":[{"name":"Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University Dresden, 01309 Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Behrens","sequence":"additional","affiliation":[{"name":"Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University Dresden, 01309 Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7524-7628","authenticated-orcid":false,"given":"Dirk","family":"Schriefer","sequence":"additional","affiliation":[{"name":"Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University Dresden, 01309 Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8202","authenticated-orcid":false,"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[{"name":"Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University Dresden, 01309 Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"2055217318760642","article-title":"No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a","volume":"4","author":"Arnold","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: Current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","article-title":"Ocrelizumab: A Review in Multiple Sclerosis","volume":"32","author":"Syed","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e940","DOI":"10.1212\/NXI.0000000000000940","article-title":"Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS","volume":"8","author":"Kuhle","year":"2021","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1212\/NXI.0000000000000695","article-title":"Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS","volume":"7","author":"Novi","year":"2020","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1212\/NXI.0000000000001157","article-title":"Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab","volume":"9","author":"Landi","year":"2022","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eci.10.90","article-title":"Acute infusion reactions induced by monoclonal antibody therapy","volume":"7","author":"Maggi","year":"2011","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/NXI.0000000000000228","article-title":"Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS","volume":"3","author":"Thomas","year":"2016","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_14","unstructured":"European Medicines Agency (2021, December 03). Ocrevus 300 mg Concentrate for Solution for Infusion: EU Summary of Product Characteristics. Available online: https:\/\/wwwemaeuropaeu\/en\/documents\/product-information\/ocrevus-epar-product-information_enpdf."},{"key":"ref_15","first-page":"790","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial","volume":"29","author":"Vermersch","year":"2022","journal-title":"Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/brain\/119.1.225","article-title":"Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis","volume":"119","author":"Moreau","year":"1996","journal-title":"Brain A J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/135245859600100616","article-title":"CAMPATH-IH in multiple sclerosis","volume":"1","author":"Moreau","year":"1996","journal-title":"Mult. Scler."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102492","DOI":"10.1016\/j.msard.2020.102492","article-title":"Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis","volume":"46","author":"Hartung","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103448","DOI":"10.1016\/j.msard.2021.103448","article-title":"CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis","volume":"57","author":"Baker","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Fawaz","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gingele, S., Jacobus, T.L., Konen, F.F., H\u00fcmmert, M.W., S\u00fchs, K.-W., Schwenkenbecher, P., Ahlbrecht, J., M\u00f6hn, N., M\u00fcschen, L.H., and B\u00f6nig, L. (2018). Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients. Cells, 8.","DOI":"10.3390\/cells8010012"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of Human CD3+CD20+ T Cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0163-4453(91)92538-G","article-title":"C-reactive protein sufficient as screening test in bacterial vs. viral infections","volume":"23","author":"Aufweber","year":"1991","journal-title":"J. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Massaro, K.S., Costa, S.F., Leone, C., and Chamone, D.A. (2007). Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect. Dis., 7.","DOI":"10.1186\/1471-2334-7-137"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/13759\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:56Z","timestamp":1760145176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/13759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":27,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232213759"],"URL":"https:\/\/doi.org\/10.3390\/ijms232213759","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]}}}